[866] Antibiotic Resistance

Our research group is currently conducting several clinical and epidemiological studies to evaluate key questions related to the burden and control of the acquisition, transmission and infection by multidrug-resistant microorganisms. We collaborate closely with the Genomics Research Laboratory at HUG, based on a productive translational research platform. The most notable examples of our research are the evaluation of different MRSA control interventions (JAMA 2008, BMJopen 2013, Nature Rev Dis Primer 2018), the advanced analysis of epidemiologic trends and the burden of multiresistant microorganisms (EuroSurv 2016, Lancet Infect Dis 2019), the conduct of epidemiologic studies linking patient data with molecular investigations (Clin Infect Dis 2011, J Infect Dis 2016), the evaluation of antibiotic stewardship interventions (Lancet Infect Dis 2010, JAMA 2018, JAMA 2020) and several placebo-controlled, randomised clinical trials to decolonise MRSA and ESBL carriers (JAC 2013; JAC 2015) or prevent ESBL infections (Lancet Infect Dis 2017, Clin Microbiol Infect 2019, Lancet Infect Dis 2020).   Furthermore, we currently participate in several large-scale European research networks tackling various aspects of antibiotic resistance, including improved clinical trial design (COMBACTE and ECRAID), improved burden of resistance estimations and predictions (PRIMAVERA) and improved implementation of AMR control measures (REVERSE).